Substituted bicyclic imidazole derivatives as gamma secretase modulators

A compound of formula (I)

• or a stereoisomeric form thereof, wherein
• R0 is hydrogen, halo or C1-4alkyl;
• R1 is hydrogen, C1-4alkyl or halo;
• X is CR7 or N;
• wherein R7 is hydrogen or halo;
• A1 is CR2 or N;
• A2 is CR8 or N;
• A3 and A4 each independently are CH or N;
• provided that no more than two of A1, A2, A3 and A4 are N;
• R2 is hydrogen, halo or C1-4alkyloxy;
• R8 is hydrogen or halo;
• R3 is hydrogen;
• C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl, halo, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, Ar, C1-6alkyloxy, cycloC3-7alkyloxy, and cycloC3-7alkyl;
• carboxyl;
• C2-4alkenyl;
• NR5R6-carbonyl;
• cycloC3-7alkyl;
• Ar;
• tetrahydropyranyl;
• C1-6alkylcarbonyl;
• C1-6alkyloxycarbonyl;
• or Ar—O—CH2—;
• wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR5R6, morpholinyl, C1-4alkyl, and C1-4alkyl substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, and NR5R6;
• benzimidazolyl optionally substituted with one or more substituents each independently selected from C1-4alkyl;
• or pyridinyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl, and C1-4alkyl substituted with one or more substituents each independently selected from halo;
• each R5 independently is hydrogen, C1-4alkyl, C1-6alkylcarbonyl,
• or C1-4alkyloxy(CH2CH2O)n—CH2-carbonyl;
• n is an integer selected from 1, 2, 3, 4, 5 or 6.
• each R6 independently is hydrogen or C1-4alkyl;
• R4 is hydrogen;
• cyano;
• halo;
• phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and phenyl;
• phenylcarbonyl optionally substituted with one or more substituents each independently selected from halo;
• C1-4alkyloxy;
• C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, NR5R6, C1-4alkyloxy, hydroxyl, and formylamino;
• Y1 is CH or N;
• Y2 is CR9 or N;
• Y3 is CH or N;
• provided that only one of Y1, Y2 and Y3 may represent N;
• R9 is hydrogen;
• halo;
• C1-4alkyloxy;
• cyano;
• cycloC3-7alkyl;
• tetrahydropyranyl;
• C2-4alkenyl;
• phenyl optionally substituted with one or more substituents each independently selected from C1-4alkyloxy;
• or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
• or a pharmaceutically acceptable addition salt or a solvate thereof.